Key clinical point: Concomitant emicizumab prophylaxis and immune tolerance induction (ITI) appears suitable for bleeding prevention in pediatric patients with severe hemophilia A and inhibitors.
Major finding: In total, three patients attained a negative inhibitor titer of less than 0.6 CBU/mL, and two patients had a normal FVIII recovery of greater than or equal to 66%.
Study details: A retrospective analysis of seven pediatric patients with severe hemophilia A and inhibitors.
Disclosures: No funding sources were reported. The authors reported financial affiliations with Bayer, Bioverativ, CSL Behring, Cat-alyst Biosciences, Genentech, HEMA Biologics, Novo Nordisk, Octapharma, and several others.
Batsuli G et al. Haemophilia. 2019 Aug 2. doi: 10.1111/hae.13819.